{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T23:49:14Z","timestamp":1792194554693,"version":"4.4.0"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,26]],"date-time":"2021-08-26T00:00:00Z","timestamp":1629936000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.lungcan.2021.08.011","type":"journal-article","created":{"date-parts":[[2021,8,27]],"date-time":"2021-08-27T11:03:40Z","timestamp":1630062220000},"page":"99-110","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":51,"special_numbering":"C","title":["Tumor Treating Fields (TTFields) downregulate the Fanconi Anemia-BRCA pathway and increase the efficacy of chemotherapy in malignant pleural mesothelioma preclinical models"],"prefix":"10.1016","volume":"160","author":[{"given":"Helena","family":"Mumblat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia","family":"Martinez-Conde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ori","family":"Braten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mijal","family":"Munster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eyal","family":"Dor-On","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa S.","family":"Schneiderman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaara","family":"Porat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tali","family":"Voloshin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiri","family":"Davidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roni","family":"Blatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Shteingauz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Tempel-Brami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Einav","family":"Zeevi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Lajterer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuval","family":"Shmueli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiri","family":"Danilov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adi","family":"Haber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moshe","family":"Giladi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uri","family":"Weinberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Kinzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoram","family":"Palti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.lungcan.2021.08.011_b0005","first-page":"2531","article-title":"Curcumin induces apoptosis and inhibits angiogenesis in murine malignant mesothelioma","volume":"53","author":"Zhang","year":"2018","journal-title":"Int. J. Oncol."},{"issue":"7","key":"10.1016\/j.lungcan.2021.08.011_b0010","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1038\/cdd.2015.165","article-title":"Molecular profiling reveals primary mesothelioma cell lines recapitulate human disease","volume":"23","author":"Chernova","year":"2016","journal-title":"Cell Death Differ."},{"issue":"8","key":"10.1016\/j.lungcan.2021.08.011_b0015","doi-asserted-by":"crossref","first-page":"2818","DOI":"10.1158\/1078-0432.CCR-08-1579","article-title":"Valproate, in combination with pemetrexed and cisplatin, provides additional efficacy to the treatment of malignant mesothelioma","volume":"15","author":"Vandermeers","year":"2009","journal-title":"Clin. Cancer Res."},{"issue":"14","key":"10.1016\/j.lungcan.2021.08.011_b0020","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J. Clin. Oncol."},{"issue":"10026","key":"10.1016\/j.lungcan.2021.08.011_b0025","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","article-title":"Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial","volume":"387","author":"Zalcman","year":"2016","journal-title":"Lancet"},{"issue":"13","key":"10.1016\/j.lungcan.2021.08.011_b0030","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1200\/JCO.2017.76.6394","article-title":"Treatment of malignant pleural mesothelioma: american society of clinical oncology clinical practice guideline","volume":"36","author":"Kindler","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"10272","key":"10.1016\/j.lungcan.2021.08.011_b0035","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"Baas","year":"2021","journal-title":"Lancet"},{"issue":"S2","key":"10.1016\/j.lungcan.2021.08.011_b0040","doi-asserted-by":"crossref","first-page":"S276","DOI":"10.21037\/jtd.2017.10.125","article-title":"The pathological and molecular diagnosis of malignant pleural mesothelioma: a literature review","volume":"10","author":"Al\u00ec","year":"2018","journal-title":"J. Thoracic Dis."},{"issue":"24","key":"10.1016\/j.lungcan.2021.08.011_b0045","doi-asserted-by":"crossref","first-page":"10152","DOI":"10.1073\/pnas.0702916104","article-title":"Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors","volume":"104","author":"Kirson","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"issue":"9","key":"10.1016\/j.lungcan.2021.08.011_b0050","doi-asserted-by":"crossref","first-page":"3288","DOI":"10.1158\/0008-5472.CAN-04-0083","article-title":"Disruption of cancer cell replication by alternating electric fields","volume":"64","author":"Kirson","year":"2004","journal-title":"Cancer Res."},{"issue":"12","key":"10.1016\/j.lungcan.2021.08.011_b0055","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1016\/S1470-2045(19)30532-7","article-title":"Tumour Treating Fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): a multicentre, single-arm phase 2 trial","volume":"20","author":"Ceresoli","year":"2019","journal-title":"Lancet Oncol."},{"issue":"14","key":"10.1016\/j.lungcan.2021.08.011_b0060","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1016\/j.ejca.2012.04.011","article-title":"NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality","volume":"48","author":"Stupp","year":"2012","journal-title":"Eur. J. Cancer"},{"issue":"23","key":"10.1016\/j.lungcan.2021.08.011_b0065","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1001\/jama.2015.16669","article-title":"Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma: A randomized clinical trial","volume":"314","author":"Stupp","year":"2015","journal-title":"JAMA"},{"issue":"23","key":"10.1016\/j.lungcan.2021.08.011_b0070","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1001\/jama.2017.18718","article-title":"Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial","volume":"318","author":"Stupp","year":"2017","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.lungcan.2021.08.011_b0075","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/s41416-020-01136-5","article-title":"Tumour treating fields therapy for glioblastoma: current advances and future directions","volume":"124","author":"Rominiyi","year":"2021","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.lungcan.2021.08.011_b0080","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1053\/j.seminoncol.2014.09.006","article-title":"Alternating electric fields (tumor-treating fields therapy) can improve chemotherapy treatment efficacy in non-small cell lung cancer both in vitro and in vivo","volume":"41","author":"Giladi","year":"2014","journal-title":"Semin. Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2021.08.011_b0085","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.pan.2013.11.009","article-title":"Mitotic disruption and reduced clonogenicity of pancreatic cancer cells in vitro and in vivo by tumor treating fields","volume":"14","author":"Giladi","year":"2014","journal-title":"Pancreatology"},{"issue":"12","key":"10.1016\/j.lungcan.2021.08.011_b0090","doi-asserted-by":"crossref","first-page":"2850","DOI":"10.1002\/ijc.30406","article-title":"Alternating electric fields (TTFields) in combination with paclitaxel are therapeutically effective against ovarian cancer cells in vitro and in vivo","volume":"139","author":"Voloshin","year":"2016","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.lungcan.2021.08.011_b0095","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1053\/j.seminoncol.2014.09.008","article-title":"Post Hoc analyses of intention-to-treat population in phase III comparison of NovoTTF-100A system versus best physician's choice chemotherapy","volume":"41","author":"Kanner","year":"2014","journal-title":"Semin. Oncol."},{"issue":"5","key":"10.1016\/j.lungcan.2021.08.011_b0100","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/j.ijrobp.2019.04.008","article-title":"Correlation of tumor treating fields dosimetry to survival outcomes in newly diagnosed glioblastoma: a large-scale numerical simulation-based analysis of data from the phase 3 EF-14 randomized trial","volume":"104","author":"Ballo","year":"2019","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"2","key":"10.1016\/j.lungcan.2021.08.011_b0105","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s11060-018-03057-z","article-title":"Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: a subgroup analysis of the EF-14 phase III trial","volume":"141","author":"Toms","year":"2019","journal-title":"J. Neurooncol."},{"issue":"5","key":"10.1016\/j.lungcan.2021.08.011_b0110","doi-asserted-by":"crossref","first-page":"e0125269","DOI":"10.1371\/journal.pone.0125269","article-title":"Tumor treating fields perturb the localization of septins and cause aberrant mitotic exit","volume":"10","author":"Gera","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.lungcan.2021.08.011_b0115","doi-asserted-by":"crossref","first-page":"18046","DOI":"10.1038\/srep18046","article-title":"Mitotic spindle disruption by alternating electric fields leads to improper chromosome segregation and mitotic catastrophe in cancer cells","volume":"5","author":"Giladi","year":"2015","journal-title":"Sci. Rep."},{"issue":"11","key":"10.1016\/j.lungcan.2021.08.011_b0120","doi-asserted-by":"crossref","first-page":"3684","DOI":"10.3390\/ijms19113684","article-title":"Functional biological activity of sorafenib as a tumor-treating field sensitizer for glioblastoma therapy","volume":"19","author":"Jo","year":"2018","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.lungcan.2021.08.011_b0125","doi-asserted-by":"crossref","first-page":"e2711","DOI":"10.1038\/cddis.2017.136","article-title":"Tumor-treating fields elicit a conditional vulnerability to ionizing radiation via the downregulation of BRCA1 signaling and reduced DNA double-strand break repair capacity in non-small cell lung cancer cell lines","volume":"8","author":"Karanam","year":"2017","journal-title":"Cell Death Dis."},{"issue":"1","key":"10.1016\/j.lungcan.2021.08.011_b0130","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1186\/s13014-017-0941-6","article-title":"Tumor treating fields (TTFields) delay DNA damage repair following radiation treatment of glioma cells","volume":"12","author":"Giladi","year":"2017","journal-title":"Radiat. Oncol."},{"issue":"38","key":"10.1016\/j.lungcan.2021.08.011_b0135","doi-asserted-by":"crossref","first-page":"62267","DOI":"10.18632\/oncotarget.11407","article-title":"Biological effect of an alternating electric field on cell proliferation and synergistic antimitotic effect in combination with ionizing radiation","volume":"7","author":"Kim","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.lungcan.2021.08.011_b0140","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.trsl.2019.10.003","article-title":"Tumor treating fields cause replication stress and interfere with DNA replication fork maintenance: implications for cancer therapy","volume":"217","author":"Karanam","year":"2020","journal-title":"Transl. Res."},{"issue":"1","key":"10.1016\/j.lungcan.2021.08.011_b0145","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1158\/1078-0432.CCR-06-1637","article-title":"Targeting fanconi anemia\/BRCA2 pathway defects in cancer: the significance of preclinical pharmacogenomic models","volume":"13","author":"Gallmeier","year":"2007","journal-title":"Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.lungcan.2021.08.011_b0150","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1016\/j.celrep.2020.01.052","article-title":"Cooperation of the ATM and fanconi anemia\/BRCA pathways in double-strand break end resection","volume":"30","author":"Cai","year":"2020","journal-title":"Cell Rep."},{"key":"10.1016\/j.lungcan.2021.08.011_b0155","doi-asserted-by":"crossref","unstructured":"Blatt, R., et al., In vivo safety of Tumor Treating Fields (TTFields) applied to the torso. Under review, 2021.","DOI":"10.3389\/fonc.2021.670809"},{"issue":"6","key":"10.1016\/j.lungcan.2021.08.011_b0160","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1177\/030098589803500601","article-title":"The cell cycle: a review","volume":"35","author":"Schafer","year":"1998","journal-title":"Vet. Pathol."},{"issue":"1","key":"10.1016\/j.lungcan.2021.08.011_b0165","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1146\/annurev-cancerbio-040716-075628","article-title":"Cell cycle-targeted cancer therapies","volume":"1","author":"Sherr","year":"2017","journal-title":"Ann. Rev. Cancer Biol."},{"issue":"3","key":"10.1016\/j.lungcan.2021.08.011_b0170","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1046\/j.1365-2184.2003.00266.x","article-title":"The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer","volume":"36","author":"Vermeulen","year":"2003","journal-title":"Cell Prolif."},{"issue":"11","key":"10.1016\/j.lungcan.2021.08.011_b0175","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.3390\/ijms17111818","article-title":"Transition metal intercalators as anticancer agents-recent advances","volume":"17","author":"Deo","year":"2016","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.lungcan.2021.08.011_b0180","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.drup.2012.07.002","article-title":"Antifolates in cancer therapy: structure, activity and mechanisms of drug resistance","volume":"15","author":"Gonen","year":"2012","journal-title":"Drug Resist. Updates"},{"issue":"13","key":"10.1016\/j.lungcan.2021.08.011_b0185","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1101\/gad.195248.112","article-title":"Regulation of DNA cross-link repair by the Fanconi anemia\/BRCA pathway","volume":"26","author":"Kim","year":"2012","journal-title":"Genes Dev."},{"issue":"24","key":"10.1016\/j.lungcan.2021.08.011_b0190","doi-asserted-by":"crossref","first-page":"2925","DOI":"10.1101\/gad.1370505","article-title":"The Fanconi Anemia\/BRCA pathway: new faces in the crowd","volume":"19","author":"Kennedy","year":"2005","journal-title":"Genes Dev."},{"issue":"4","key":"10.1016\/j.lungcan.2021.08.011_b0195","doi-asserted-by":"crossref","first-page":"435","DOI":"10.3390\/jcm8040435","article-title":"PARP inhibitors as a therapeutic agent for homologous recombination deficiency in breast cancers","volume":"8","author":"Keung","year":"2019","journal-title":"J. Clin. Med."},{"issue":"12","key":"10.1016\/j.lungcan.2021.08.011_b0200","doi-asserted-by":"crossref","DOI":"10.3390\/cancers10120487","article-title":"Role of BRCA mutations in cancer treatment with Poly(ADP-ribose) polymerase (PARP) inhibitors","volume":"10","author":"Faraoni","year":"2018","journal-title":"Cancers"},{"issue":"101","key":"10.1016\/j.lungcan.2021.08.011_b0205","article-title":"Preclinical models of malignant mesothelioma","volume":"10","author":"Testa","year":"2020","journal-title":"Front. Oncol."},{"issue":"16","key":"10.1016\/j.lungcan.2021.08.011_b0210","doi-asserted-by":"crossref","first-page":"4282","DOI":"10.1158\/0008-5472.CAN-13-3109","article-title":"Germline mutations in BAP1 impair its function in DNA double-strand break repair","volume":"74","author":"Ismail","year":"2014","journal-title":"Cancer Res."},{"issue":"7","key":"10.1016\/j.lungcan.2021.08.011_b0215","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1007\/s00262-020-02534-7","article-title":"Tumor-treating fields (TTFields) induce immunogenic cell death resulting in enhanced antitumor efficacy when combined with anti-PD-1 therapy","volume":"69","author":"Voloshin","year":"2020","journal-title":"Cancer Immunol. Immunother."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500221005122?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500221005122?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T12:56:17Z","timestamp":1759236977000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500221005122"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":43,"alternative-id":["S0169500221005122"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2021.08.011","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tumor Treating Fields (TTFields) downregulate the Fanconi Anemia-BRCA pathway and increase the efficacy of chemotherapy in malignant pleural mesothelioma preclinical models","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2021.08.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}